Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?

Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Michel D. Kazatchkine, Srini V. Kaveri

Research output: Contribution to journalArticle

70 Scopus citations

Abstract

The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
Original languageEnglish
JournalTrends in Pharmacological Sciences
Volume25
Issue number6
DOIs
StatePublished - 1 Jan 2004

Fingerprint Dive into the research topics of 'Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?'. Together they form a unique fingerprint.

  • Cite this